Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer

NCT02875613 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Slow patient accrual

Conditions

Nasopharyngeal Cancer

Interventions

DRUG: Avelumab

Sponsor

Assuntina Sacco, M.D.

Collaborators

[object Object]